Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Iron Catalyzed Hydrogen Sulfide and Its Prevalence during Oxidative Events in Sickle Cell Disease

Jie Yang, PhD, Nazmin Bithi, B.Sc, Christopher Link, B.Sc, Yogenthiran Saunthararajah, MD, Christopher Hine, PhD

Blood (2019) 134 (Supplement_1): 3534.

https://doi.org/10.1182/blood-2019-122985

Published: 2019

Journal Articles

Effect of Metabolic Reprogramming on the Biological Activity of Acute Myeloid Leukemia Cells

Tongyuan Liu, MD, Dengju Li, MD, Jianfeng Zhou, PhD

Blood (2018) 132 (Supplement 1): 5227.

https://doi.org/10.1182/blood-2018-99-115654

Published: 2018

Journal Articles

Determinants of Early Death and Outcomes for Acute Promyelocytic Leukemia in the Arsenic Era: A Real World Study

Honghu Zhu, Jinsong Jia, Jiang Qian, PhD, Hao Jiang, MD, Jin Lu, Bin Jiang, Xiaojun Huang

Blood (2017) 130 (Supplement 1): 1340.

https://doi.org/10.1182/blood.V130.Suppl_1.1340.1340

Published: 2017

Journal Articles

Targeting Systemic Inflammatory Response Syndrome As Initial Therapy and Oral Arsenic Based Consolidation Regimen for Acute Promyelocytic Leukemia

Stephen Yang Liang, MD

Blood (2017) 130 (Supplement 1): 1333.

https://doi.org/10.1182/blood.V130.Suppl_1.1333.1333

Published: 2017

Journal Articles

Targeting Glutamine Metabolism in Myeloproliferative Neoplasms

Huichun Zhan, MD, Geoffrey Girnun, PhD, Katherine Dong, Kristen Ciano, M.S., Yupo Ma, MD PhD, Stanley Zucker, MD

Blood (2014) 124 (21): 1869.

https://doi.org/10.1182/blood.V124.21.1869.1869

Published: 2014

Journal Articles

Nanoparticle Arsenic Compound Realgar Effectively Targets Myeloma Stem-Like Side Population

Jana Jakubikova, PhD, Teru Hideshima, MD, PhD, Richard W.J. Groen, PhD, Danka Cholujova, PhD, Zdenka Bujnakova, PhD, Jacob P. Laubach, MD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Constantine S. Mitsiades, MD, PhD, Peter Balaz, PhD, Jan Sedlak, PhD, Kenneth C. Anderson, MD

Blood (2013) 122 (21): 4455.

https://doi.org/10.1182/blood.V122.21.4455.4455

Published: 2013

Journal Articles

Glutaminase Inhibition Selectively Slows the Growth of Primary Acute Myeloid Leukemia (AML) Cells with Isocitrate Dehydrogenase ( IDH ) Mutations.

Ashkan Emadi, M.D., Ph.D., Sung Ah Jun, BSc, Takashi Tsukamoto, Ph.D., Amir T Fathi, MD, Mark D. Minden, MD, PhD, Chi Van Dang, M.D., Ph.D.

Blood (2012) 120 (21): 2624.

https://doi.org/10.1182/blood.V120.21.2624.2624

Published: 2012

Journal Articles

Arsenic Sulfide Binds c-CBL to Promote BCR-ABL Ubiquitination and Degradation In Chronic Myelogenous Leukemia.

Jian-Hua Mao, Xiao-Yan Sun, Jian-Xiang Liu, Qun-Ye Zhang, Ping Liu, Qiu-Hua Huang, Ke-Qin Li, Xiao-Wei Zhang, Quan Chen, Zhu Chen, Sai-Juan Chen

Blood (2010) 116 (21): 1200.

https://doi.org/10.1182/blood.V116.21.1200.1200

Published: 2010

Journal Articles

Arsenic Containing Triple-Agent Therapy for Acute Promyelocytic Leukemia-Comparison of Tetra-Arsenic Tetra-Sulfide vs. Arsenic Trioxide in the Long-Term Follow-up at a Single Hospital.

Shu-Lan Wu, MD, Dao-Pei Lu, MD, Yan-Li Zhao, MD, Lan-Qing Liang, MD, Jun-Bao He, MD, Wei Zou, MD, Xin-Hong Fei, MD, Bin Jiang, MD, Fu-Xiang Shan, MD, Ping-Di Yang, MD, Jie Zhao, MD, Chun-Rong Tong, MD

Blood (2010) 116 (21): 1081.

https://doi.org/10.1182/blood.V116.21.1081.1081

Published: 2010

Journal Articles

Targeting the 5-Lipoxygenase as a Novel Principle of Stem Cell Therapy In Acute Myeloid Leukemia

Jessica Roos, Astrid Fischer, Dieter Steinhilber, Hubert Serve, Oliver Ottmann, Thorsten Maier, Martin Ruthardt

Blood (2010) 116 (21): 1846.

https://doi.org/10.1182/blood.V116.21.1846.1846

Published: 2010

Journal Articles

Molecular and Cellular Specialization of Iron Regulation In Human Erythroid Progenitor Cells Prior to Hemoglobin Production

Seung-Jae Noh, PhD, Colleen Byrnes, Y. Terry Lee, Jeffery L. Miller

Blood (2010) 116 (21): 4255.

https://doi.org/10.1182/blood.V116.21.4255.4255

Published: 2010

Journal Articles

E3 Ligase c-CBL Mediates Ubiquitination-Proteasomal Degradation of BCR-ABL and Therapeutic Effects against BCR-ABL Leukemia.

Jianhua Mao, PHD, Xiaoyan Sun, PHD, candidate, Qun-Ye Zhang, Qiu-Hua Huang, Ping Liu, Yinyin Xie, Bachelor, Jing Lu, Saijuan Chen, Zhu Chen

Blood (2009) 114 (22): 3257.

https://doi.org/10.1182/blood.V114.22.3257.3257

Published: 2009

Journal Articles

Synthetic Peptide Mimotopes of blood Group Antigens for Red Cell Antibody Screening

Evelyn J A Tait, BSc, PhD, Robin Fraser, BSc, PhD, Michael Moss, BSc, PhD, Stanislaw J Urbaniak, MBChB, PhD, FRCP, FRCPath

Blood (2008) 112 (11): 291.

https://doi.org/10.1182/blood.V112.11.291.291

Published: 2008

Journal Articles

Systems Understanding of Synergism Between As4S4 and Imatinib in Treating BCR/ABL Leukemia Model and in Attenuating BCR/ABL Oncoprotein as Well as Related Regulatory Networks

Qun-Ye Zhang, Jian-Hua Mao, Ping Liu, Qiu-Hua Huang, Jing Lu, Yan Zhang, Lin Weng, Quan Chen, Sai-Juan Chen, Zhu Chen

Blood (2008) 112 (11): 4234.

https://doi.org/10.1182/blood.V112.11.4234.4234

Published: 2008

Journal Articles

Ap-1 Family Members C-Jun, JunB and Fra-2 Mediate Apoptosis and Differentiation in AML through Activation of GADD45á and ADFP Following Non-Steroidal Anti-Inflammatory Drug Treatment.

Akos Czibere, MD, PhD, Raminder Singh, PhD, Ingmar Bruns, MD, PhD, Luiz Fernando Zerbini, PhD, Rainer Haas

Blood (2008) 112 (11): 1196.

https://doi.org/10.1182/blood.V112.11.1196.1196

Published: 2008

Journal Articles

Sulindac Sulfide Reverts the Activation of the WNT-Signaling and Aberrant Self Renewal Induced by the AML-Associated Fusion Proteins PML/RARα and PLZF/RARα.

Gunnar Steinert, Anita Seshire, PhD, Dieter Hoelzer, MD, PhD, Martin Ruthardt, MD, Elena Puccetti, PhD

Blood (2007) 110 (11): 878.

https://doi.org/10.1182/blood.V110.11.878.878

Published: 2007

Journal Articles

Tetra-Arsenic Tetra-Sulfide Containing Triple-Agent Regimen as the First Line Therapy for Acute Promyelocytic Leukemia: Expeditiously Consecutive Complete Remission and Improved Disease-Free Survival.

Tong Wu, MD, Jie Zhao, M.D., Bin Jiang, M.D., Shu-Lan Wu, M.D., Ping-Di Yang, M.D., Fu-Xiang Shan, M.D., Chun-Rong Tong, M.D., Dao-Pei Lu, M.D.

Blood (2007) 110 (11): 591.

https://doi.org/10.1182/blood.V110.11.591.591

Published: 2007

Journal Articles

Phase I Clinical Study of Imatinib Mesylate in Combination with Tetra-Arsenic Tetra-Sulfide in the Treatment of CML Patients in Advanced Phase.

Junmin Li

Blood (2005) 106 (11): 4855.

https://doi.org/10.1182/blood.V106.11.4855.4855

Published: 2005

Journal Articles

Combined Effects of As4S4 and Imatinib on Chronic Myeloid Leukemia Cells and BCR-ABL Oncoprotein.

Tong Yin, Ying-Li Wu, Hui-Ping Sun, Guan-Lin Sun, Ji Zhang, Guo-Qiang Chen, Sai-Juan Chen, Zhu Chen

Blood (2004) 104 (11): 4651.

https://doi.org/10.1182/blood.V104.11.4651.4651

Published: 2004

Journal Articles

Phase I Clinical Trial of Glivec in Combination with Tetra-Arsenic Tetra-Sulfide in the Treatment of CML Patients in Advanced Phase.

Jun-Min Li, Ai-Hua Wang, Hui-Ping Sun, Yang Shen, Rui-Hua Zhao, Bai-Wei Gu, Bing Chen, Wen Xing, Zhi-Xiang Shen, Zhen-Yi Wang, Sai-Juan Chen, Zhu Chen

Blood (2004) 104 (11): 4653.

https://doi.org/10.1182/blood.V104.11.4653.4653

Published: 2004

NARROW

Iron Catalyzed Hydrogen Sulfide and Its Prevalence during Oxidative Events in Sickle Cell Disease

Effect of Metabolic Reprogramming on the Biological Activity of Acute Myeloid Leukemia Cells

Determinants of Early Death and Outcomes for Acute Promyelocytic Leukemia in the Arsenic Era: A Real World Study

Targeting Systemic Inflammatory Response Syndrome As Initial Therapy and Oral Arsenic Based Consolidation Regimen for Acute Promyelocytic Leukemia

Targeting Glutamine Metabolism in Myeloproliferative Neoplasms

Nanoparticle Arsenic Compound Realgar Effectively Targets Myeloma Stem-Like Side Population

Glutaminase Inhibition Selectively Slows the Growth of Primary Acute Myeloid Leukemia (AML) Cells with Isocitrate Dehydrogenase ( IDH ) Mutations.

Arsenic Sulfide Binds c-CBL to Promote BCR-ABL Ubiquitination and Degradation In Chronic Myelogenous Leukemia.

Arsenic Containing Triple-Agent Therapy for Acute Promyelocytic Leukemia-Comparison of Tetra-Arsenic Tetra-Sulfide vs. Arsenic Trioxide in the Long-Term Follow-up at a Single Hospital.

Targeting the 5-Lipoxygenase as a Novel Principle of Stem Cell Therapy In Acute Myeloid Leukemia

Molecular and Cellular Specialization of Iron Regulation In Human Erythroid Progenitor Cells Prior to Hemoglobin Production

E3 Ligase c-CBL Mediates Ubiquitination-Proteasomal Degradation of BCR-ABL and Therapeutic Effects against BCR-ABL Leukemia.

Synthetic Peptide Mimotopes of blood Group Antigens for Red Cell Antibody Screening

Systems Understanding of Synergism Between As4S4 and Imatinib in Treating BCR/ABL Leukemia Model and in Attenuating BCR/ABL Oncoprotein as Well as Related Regulatory Networks

Ap-1 Family Members C-Jun, JunB and Fra-2 Mediate Apoptosis and Differentiation in AML through Activation of GADD45á and ADFP Following Non-Steroidal Anti-Inflammatory Drug Treatment.

Sulindac Sulfide Reverts the Activation of the WNT-Signaling and Aberrant Self Renewal Induced by the AML-Associated Fusion Proteins PML/RARα and PLZF/RARα.

Tetra-Arsenic Tetra-Sulfide Containing Triple-Agent Regimen as the First Line Therapy for Acute Promyelocytic Leukemia: Expeditiously Consecutive Complete Remission and Improved Disease-Free Survival.

Phase I Clinical Study of Imatinib Mesylate in Combination with Tetra-Arsenic Tetra-Sulfide in the Treatment of CML Patients in Advanced Phase.

Combined Effects of As4S4 and Imatinib on Chronic Myeloid Leukemia Cells and BCR-ABL Oncoprotein.

Phase I Clinical Trial of Glivec in Combination with Tetra-Arsenic Tetra-Sulfide in the Treatment of CML Patients in Advanced Phase.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only